Xeris Biopharma (NASDAQ:XERS) Price Target Raised to $6.50 at Craig Hallum

Xeris Biopharma (NASDAQ:XERS) had its price target hoisted by Craig Hallum from $5.00 to $6.50 in a research report sent to investors on Friday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other equities analysts have also recently issued reports on the stock. Piper Sandler reaffirmed a “neutral” rating and issued a $4.00 price objective (up previously from $3.00) on shares of Xeris Biopharma in a research note on Friday. HC Wainwright restated a “buy” rating and set a $8.00 price objective (up from $6.60) on shares of Xeris Biopharma in a research report on Friday. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $6.00 target price (up previously from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $5.90.

Xeris Biopharma Stock Up 2.7 %

Shares of NASDAQ:XERS opened at $4.24 on Friday. The company’s 50-day moving average price is $3.57 and its 200 day moving average price is $3.26. The company has a market cap of $632.10 million, a PE ratio of -9.42 and a beta of 2.32. Xeris Biopharma has a fifty-two week low of $1.69 and a fifty-two week high of $4.50.

Institutional Investors Weigh In On Xeris Biopharma

Hedge funds have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. raised its position in shares of Xeris Biopharma by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 31,611 shares of the company’s stock worth $107,000 after acquiring an additional 2,954 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Xeris Biopharma by 4.5% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 80,388 shares of the company’s stock worth $273,000 after acquiring an additional 3,447 shares in the last quarter. GPS Wealth Strategies Group LLC lifted its holdings in shares of Xeris Biopharma by 6.2% during the 4th quarter. GPS Wealth Strategies Group LLC now owns 66,925 shares of the company’s stock valued at $227,000 after purchasing an additional 3,900 shares in the last quarter. Janney Montgomery Scott LLC grew its position in shares of Xeris Biopharma by 31.4% in the 4th quarter. Janney Montgomery Scott LLC now owns 23,000 shares of the company’s stock valued at $78,000 after purchasing an additional 5,500 shares during the period. Finally, Prudential Financial Inc. increased its stake in Xeris Biopharma by 23.4% during the 4th quarter. Prudential Financial Inc. now owns 36,945 shares of the company’s stock worth $125,000 after purchasing an additional 7,000 shares in the last quarter. Institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.